Press Release: Synexus continues to build in Eastern Europe, opening a new regional center to support global clinical trials
Synexus has today opened a regional office for Eastern Europe in Wroclaw, Poland. The investment reflects Synexus’ continued commitment to the region and has been created to service the important role that clients see for Eastern Europe in terms of global clinical trials.
The new 3,000 square foot office located in the Sky Tower, in one of the city’s most prestigious business districts, will house a strong regional team with experience in delivering clinical trials for Synexus clients. The extra space will allow Synexus to further strengthen this team that has over a decade of experience in Eastern Europe. The team will be responsible for Synexus’ patient engagement programs as well as the management of Synexus’ nine dedicated research centres across Poland, Hungary, Romania, Ukraine and Bulgaria.
Regional Managing Director, Dr Radoslaw Janiak commented: “Our success in the region is based on our ability to deliver patients and quality data to our clients in pharma. We have put in place a sophisticated patient engagement program which really improves the patient experience and it is these added-value extras which really pay dividends in terms of client success.”
Christophe Berthoux CEO of Synexus, who attended the opening, commented, “We have an exceptional team in Eastern Europe who have consistently met the needs of our customers. For example, it is no accident that the Wroclaw site was the first Synexus site to be selected to join Pfizer’s Inspire site network.”
Mayor of Wroclaw Rafał Dutkiewicz and Prof. Krzysztof Strojek, M.D., PhD , National Consultant in Diabetology opened the new facilities and addressed the guests who came from across the region including executives from top pharma, Amgen, Merck, Servier, AstraZeneca, NovoNordisk, Pfizer, and the world’s leading CROs, Covance, Inventiv, PPD and Parexel.
Synexus, which has more than 25 dedicated research centres across Europe and Africa, focuses on undertaking clinical trials in the therapy areas where it can provide most value – cardiovascular, metabolic (diabetes and obesity), bone, respiratory and CNS (dementia and pain).
- ENDS –
 INSPIRE, which stands for Investigator Networks, Site Partnerships and Infrastructure for Research Excellence, means that these sites have early access to Pfizer‘s portfolio data and advanced information regarding the clinical trials to be sponsored by Pfizer. They are also involved in publications in scientific journals, protocol design, advisory boards and the sharing of best practice across the INSPIRE network.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.